tci Medicare Compliance & Reimbursement - 2004 Issue 18

FDA: FDA Approves Two New Cancer Drugs

Martha Stewart may be going to prison because she bet against ImClone's new cancer drug Erbitux, but careful coding and documentation can keep physicians out of trouble with billing for this drug. Erbitux is one of two new colorectal cancer drugs that just won Food and Drug Administration approval. The other one, Genetech's Avastin, aims to treat first-line, or previously untreated, colon or rectal cancer. By contrast, Erbitux is designed to treat patients with EGFR-expressing or metastatic colorectal cancer, and particularly ones who are intolerant to irinotecan-based chemotherapy. Because these are both chemotherapy drugs, physicians should use unlisted...

To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.


Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4200 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
Access to this feature is available in the following products:
  • tci Medicare Compliance & Reimbursement +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.